Orion Portfolio Solutions LLC Trims Stock Position in Relx Plc (NYSE:RELX)

Orion Portfolio Solutions LLC reduced its position in Relx Plc (NYSE:RELX) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 209,120 shares of the technology company’s stock after selling 7,574 shares during the period. Orion Portfolio Solutions LLC’s holdings in Relx were worth $9,498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zions Bancorporation N.A. grew its position in shares of Relx by 69.0% during the 4th quarter. Zions Bancorporation N.A. now owns 69,710 shares of the technology company’s stock valued at $3,166,000 after acquiring an additional 28,454 shares during the period. Congress Wealth Management LLC DE grew its holdings in Relx by 8.7% in the fourth quarter. Congress Wealth Management LLC DE now owns 9,630 shares of the technology company’s stock valued at $437,000 after purchasing an additional 772 shares during the period. LPL Financial LLC increased its position in shares of Relx by 20.9% in the fourth quarter. LPL Financial LLC now owns 230,589 shares of the technology company’s stock valued at $10,473,000 after buying an additional 39,882 shares in the last quarter. Sei Investments Co. lifted its position in shares of Relx by 3.8% during the 4th quarter. Sei Investments Co. now owns 327,134 shares of the technology company’s stock valued at $14,859,000 after buying an additional 12,034 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Relx by 5.1% during the 4th quarter. American Century Companies Inc. now owns 405,100 shares of the technology company’s stock valued at $18,400,000 after buying an additional 19,728 shares in the last quarter. Hedge funds and other institutional investors own 15.02% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on RELX. The Goldman Sachs Group assumed coverage on shares of Relx in a research report on Wednesday. They set a “buy” rating for the company. Barclays upgraded shares of Relx from an “equal weight” rating to an “overweight” rating in a research report on Friday, March 14th. Redburn Atlantic started coverage on Relx in a report on Wednesday, January 8th. They issued a “buy” rating on the stock. Finally, StockNews.com cut Relx from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy”.

Relx Price Performance

Relx stock opened at $50.21 on Friday. The company has a fifty day simple moving average of $49.48 and a 200-day simple moving average of $47.82. The firm has a market capitalization of $93.18 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.73 and a beta of 0.90. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46. Relx Plc has a 52-week low of $40.25 and a 52-week high of $51.99.

Relx Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be paid a dividend of $0.5586 per share. This represents a yield of 1.6%. The ex-dividend date is Friday, May 9th. This is a boost from Relx’s previous semi-annual dividend of $0.23. Relx’s dividend payout ratio is currently 59.68%.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.